DOCSLIB.ORG

4519.591 Program Book Cover

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
4519.591 Program Book Cover 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies November 12-13, 2013 Lister Hill Auditorium NIH Main Campus Bethesda, Maryland Program November 12 8:00 a.m. - 8:15 a.m. Poster Setup (posters to stay up for the entire meeting) 8:15 a.m. - 8:30 a.m. Opening Remarks: Day 1 Robert Yarchoan, M.D. Office of HIV and AIDS Malignancy National Cancer Institute, NIH, USA Geraldina Dominguez, Ph.D. Office of HIV and AIDS Malignancy National Cancer Institute, NIH, USA 8:30 a.m. - 9:30 a.m. HPV Vaccines Moderator: T-C Wu, M.D., Ph.D. Johns Hopkins University, USA 8:30 a.m. - 9:00 a.m. Plenary: L2 as a Target for Prophylactic Human Papillomavirus Vaccination Richard Roden, Ph.D. Johns Hopkins University, USA 9:00 a.m. - 9:30 a.m. Plenary: HPV Vaccination in HIV-Infected Men and Women Joel Palefsky, M.D. University of California, San Francisco, USA 9:30 a.m. - 10:15 a.m. Oral HPV Moderator: Isaac R. Rodriguez-Chavez, Ph.D. National Institute of Dental and Craniofacial Research, NIH, USA 9:30 a.m. - 9:45 a.m. HIV-Induced Epithelial-Mesenchymal Transition in Oral Mucosal Epithelial Cells Facilitates HPV Infection Sharof M. Tugizov, D.V.M., Ph.D., D.Sc. University of California, San Francisco, USA 9:45 a.m. - 10:00 a.m. HIV-Related Immunosuppression Is Associated With Higher Incidence of Oral HPV, But Not Oral HPV Clearance Daniel C. Beachler, M.S.P.H. Johns Hopkins University, USA 10:00 a.m. - 10:15 a.m. HIV Tat Increases HPV16 Infectivity Independent of Oral Keratinocyte Terminal Differentiation Jennifer Webster-Cyriaque, D.D.S., Ph.D. The University of North Carolina at Chapel Hill, USA 10:15 a.m. - 10:45 a.m. Break and Poster Session - 1 ­ 10:45 a.m. - 12:15 p.m. Pathogens and Host Interactions Moderator: Corey Casper, M.D., M.P.H. Fred Hutchinson Cancer Research Center, USA 10:45 a.m. - 11:15 a.m. Plenary: Potential Role of Graft-Versus-Host Reaction in Reducing the HIV-1 Reservoir Daniel R. Kuritzkes, M.D. Brigham and Women’s Hospital, USA 11:15 a.m. - 11:30 a.m. Variation in Viral Gene Expression Distinguishes Two Subtypes of Kaposi Sarcoma Dirk P. Dittmer, Ph.D. The University of North Carolina at Chapel Hill, USA 11:30 a.m. - 11: 45 a.m. Characterization of HHV-8 Gene Expression in Kaposi Sarcoma Tumors and Correlation With Clinical Presentation and Outcomes Warren Phipps, M.D., M.P.H. Fred Hutchinson Cancer Research Center, USA 11:45 a.m. - 12 noon Prevalent High-Risk HPV Infection and Vaginal Microbiota in Nigerian Women Clement A. Adebamowo, M.D. Institute of Human Virology University of Maryland School of Medicine, Baltimore, USA 12 noon - 12:15 p.m. Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals in the Center for AIDS Research Network of Integrated Clinical Systems Satish Gopal, M.D. The University of North Carolina at Chapel Hill, USA 12:15 p.m. - 1:45 p.m. Lunch 12:45 p.m. - 1:45 p.m. Poster Session (Day 1 presenters to stand by their posters) 1:45 p.m. - 2:45 p.m. Cancer Burden in Low and Middle Income Countries Moderator: Sam Mbulaiteye, M.D. National Cancer Institute, NIH, USA 1:45 p.m. - 2:15 p.m. Plenary: Harnessing Cancer Registry and HIV Databases in Low and Middle Income Countries Diego Serraino, M.D. IRCCS Centro di Riferimento Oncologico, Italy 2:15 p.m. - 2:45 p.m. Plenary: HIV and Cancer Survival in Uganda Anna E. Coghill, Ph.D., M.P.H. National Cancer Institute, NIH, USA 2:45 p.m. - 3:30 p.m. Break and Poster Session (Lister Hill cafeteria closes at 3:00 p.m.) - 2 ­ 3:30 p.m. - 5:30 p.m. KSHV Biology Moderators: Denise Whitby, Ph.D. National Cancer Institute, NIH, USA Dirk P. Dittmer, Ph.D. The University of North Carolina at Chapel Hill, USA 3:30 p.m. - 3:45 p.m. Kaposi Sarcoma Herpesvirus (KSHV) vFLIP Induces Systemic Endothelial Proliferation and a Proinflammatory Phenotype In Vivo Gianna Ballon, M.D. Weill Cornell Medical College, USA 3:45 p.m. - 4:00 p.m. Human Herpesvirus 8 Infection Induces Polyfunctional B Lymphocytes Producing Cytokines and Chemokines That Drive Kaposi’s Sarcoma Charles R. Rinaldo, Ph.D. University of Pittsburgh, USA 4:00 p.m. - 4:15 p.m. Kaposi Sarcoma-Associated Human Herpesvirus (KSHV) Latency- Associated Nuclear Antigen (LANA) Undergoes Cleavage by Caspases Following Exposure of Cells to Oxidative Stress David A. Davis, Ph.D. National Cancer Institute, NIH, USA 4:15 p.m. - 4:30 p.m. Regulation of Kaposi Sarcoma Herpesvirus (KSHV) Encoded Viral Interleukin 6 (vIL-6) by X-Box Binding Protein 1 (XBP-1) Duosha Hu, M.D., Ph.D. National Cancer Institute, NIH, USA 4:30 p.m. - 4:45 p.m. RNA-Independent Activation of RIG-I by Deamidation Pinghui Feng, Ph.D. University of Southern California, USA 4:45 p.m. - 5:00 p.m. KSHV-Dependent Activation of Platelet Derived Growth Factor Receptor Signaling Is an Oncogenesis Driver and a Therapeutic Target in Kaposi’s Sarcoma Enrique A. Mesri, Ph.D. University of Miami, USA 5:00 p.m. - 5:15 p.m. Using Proteomics to Understand Human Target Genes of KSHV MicroRNAs Joseph M. Ziegelbauer, Ph.D. National Cancer Institute, NIH, USA 5:15 p.m. - 5:30 p.m. KS-Detect: A Complete “Sample-In, Answer-Out” Solution to the Diagnosis of Kaposi’s Sarcoma Ethel Cesarman, M.D., Ph.D. Weill Cornell Medical College, USA 5:30 p.m. End of Day 1 - 3 ­ November 13 8:00 a.m. - 8: 15 a.m. Poster Viewing 8:15 a.m. - 8:20 a.m. Welcoming Remarks: Day 2 Geraldina Dominguez, Ph.D. National Cancer Institute, NIH, USA 8:20 a.m. - 8:30 a.m. Fogarty International Center’s HIV Research Training Program Jeanne McDermott, Ph.D., M.P.H. Fogarty International Center, NIH, USA 8:30 a.m. - 9:30 a.m. Hepatitis C Virus Moderator: Ren Sun, Ph.D. University of California, Los Angeles, USA 8:30 a.m. - 9:00 a.m. Plenary: Hepatitis C and Hepatocellular Carcinoma: New Model Systems and Insights Into Pathogenesis Stanley M. Lemon, M.D. The University of North Carolina at Chapel Hill, USA 9:00 a.m. - 9:30 a.m. Plenary: Natural Courses and Management of Chronic Viral Hepatitis B or C in HIV-Infected Patients Pei-Jer Chen, M.D., Ph.D. National Taiwan University Hospital, Taiwan 9:30 a.m. - 10:15 a.m. Clinical Trials and Correlative Studies Moderator: Alexandra M. Levine, M.D. City of Hope National Medical Center, USA 9:30 a.m. - 9:45 a.m. Results of a Phase I Study of Lenalidomide in Patients With AIDS- Associated Kaposi Sarcoma (AMC 070) Kelly Shimabukuro, M.D. University of California, San Diego, USA 9:45 a.m. - 10:00 a.m. Antiretrovirals for Kaposi’s Sarcoma (ARKS): A Randomized Trial of Protease Inhibitor-Based Antiretroviral Therapy for AIDS-Associated Kaposi’s Sarcoma in Sub-Saharan Africa Jeffrey N. Martin, M.D., M.P.H. University of California, San Francisco, USA 10:00 a.m. - 10:15 a.m. Studies in Primary Cultures of Human Hepatocytes and Computer Simulations Provide Guidance for Dosing of Anticancer Drugs in Patients Treated With HAART Drugs Raman Venkataramanan, Ph.D. University of Pittsburgh, USA 10:15 a.m. - 10:45 a.m. Break and Poster Session - 4 ­ 10:45 a.m. - 12:15 p.m. EBV and Lymphomagenesis Moderators: Elliott D. Kieff, M.D., Ph.D. Harvard Medical School, USA Richard F. Ambinder, M.D., Ph.D. Johns Hopkins University School of Medicine, USA 10:45 a.m. - 11:15 a.m. Plenary: Immune Activation and Inflammation Biomarkers and Risk for AIDS-NHL Otoniel Martinez-Maza, Ph.D. University of California, Los Angeles, USA 11:15 a.m. - 11:30 a.m. Differential Expression and Prognostic Utility of Immunophenotypic Markers in Diffuse Large B-cell Lymphoma From Patients With and Without HIV Infection Chun R. Chao, Ph.D. Kaiser Permanente Southern California, USA 11:30 a.m. - 11:45 a.m. Targeting Sphingosine Kinase Induces Apoptosis and Regression of Virus-Associated Lymphoma In Vivo Chris M. Parsons, M.D. Louisiana State University Health Sciences Center, USA 11:45 a.m. - 12 noon The HIV-1 Matrix Protein and AIDS-Related Lymphoma Mark K. Lafferty, Ph.D. Institute of Human Virology, University of Maryland School of Medicine, USA 12 noon - 12: 15 p.m. Characterizing Survival in the Absence of LMP1-Mediated NFκB Signaling in the Model of EBV-Driven AIDS Lymphoma Alexander Price Duke University, USA 12:15 p.m. - 2:00 p.m. Lunch 1:00 pm. - 2:00 p.m. Poster Session (Day 2 presenters to stand by their posters) 2:00 p.m. - 2:45 p.m. Lung Cancer Moderator: Missak Haigentz, M.D. Albert Einstein College of Medicine, USA 2:00 p.m. - 2:30 p.m. Plenary: Chronic Inflammation and Lung Cancer Anil K. Chaturvedi, Ph.D. National Cancer Institute, NIH, USA 2:30 p.m. - 2:45 p.m. Inflammatory Biomarkers and CT-Detected Lung Nodules: Potential Implications for Lung Cancer Screening of HIV-Infected Patients Kristina Crothers, M.D. University of Washington School of Medicine, USA 2:45 p.m. -3:30 p.m. Break and Poster Session (Lister Hill cafeteria closes at 3:00 p.m.) - 5 ­ 3:30 p.m.
Load more

Recommended publications
  • Videx® Expanding Possibilities: a Case Study
    Videx® Expanding Possibilities: A Case Study Acquired Immune Deficiency Syndrome (AIDS) has long-standing and effective choice for building the dual- devastated millions of lives worldwide. The virus that NRTI foundation. causes AIDS, the human immunodeficiency virus (HIV), attacks immune system cells, leaving the body vulnerable to Development of Videx® illnesses that would otherwise pose little threat. In the worldwide AIDS pandemic, there are 5 million new HIV Role of NIH i infections and over 3 million deaths each year. By 1993, AIDS was the leading cause of death among persons 25 - 44 A well-established research program R & D TIMELINE years old in the United States. The hope brought by the first at the National Cancer Institute (NCI) drug approved by the Food and Drug Administration (FDA) gave it a unique capacity to screen Synthesis of ddA to attack the HIV, zidovudine, dissolved as patients rapidly compounds for anti-viral activity. Reported -- 1964 developed resistance to its therapeutic effect. The use of ddI to treat AIDS was discovered by NCI scientists Drs. ® Conversion of ddA The second anti-HIV drug approved by the FDA, Videx Robert Yarchoan, Hiroaki Mitsuya, to ddI Reported -- 1980 (didanosine, ddI), developed by Bristol-Myers Squibb in and Sam Broder, who also collaboration with the NIH, offered hope for people when spearheaded the early clinical NCI Scientists Identify zidovudine was not effective. It also helped usher in a new development of ddI. Using capacities Activity of ddI Against way of thinking about suppressing HIV infection as it developed in the “War on Cancer,” HIV -- 1985 became possible to test whether and how anti-viral drugs the NCI was able to do preclinical could be combined to obtain lasting benefits.
    [Show full text]
  • Differential Phosphorylation of Azidothymidine, Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral Blood Mononuclear Cells
    Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. W Y Gao, … , S Broder, H Mitsuya J Clin Invest. 1993;91(5):2326-2333. https://doi.org/10.1172/JCI116463. Research Article The antiviral activity of azidothymidine (AZT), dideoxycytidine (ddC), and dideoxyinosine (ddI) against HIV-1 was comparatively evaluated in PHA-stimulated PBM. The mean drug concentration which yielded 50% p24 Gag negative cultures were substantially different: 0.06, 0.2, and 6 microM for AZT, ddC, and ddI, respectively. We found that AZT was preferentially phosphorylated to its triphosphate (TP) form in PHA-PBM rather than unstimulated, resting PBM (R-PBM), producing 10- to 17-fold higher ratios of AZTTP/dTTP in PHA-PBM than in R-PBM. The phosphorylation of ddC and ddI to their TP forms was, however, much less efficient in PHA-PBM, resulting in approximately 5-fold and approximately 15- fold lower ratios of ddCTP/dCTP and ddATP/dATP, respectively, in PHA-PBM than in R-PBM. The comparative order of PHA-induced increase in cellular enzyme activities examined was: thymidine kinase > uridine kinase > deoxycytidine kinase > adenosine kinase > 5'-nucleotidase. We conclude that AZT, ddC, and ddI exert disproportionate antiviral effects depending on the activation state of the target cells, i.e., ddI and ddC exert antiviral activity more favorably in resting cells than in activated cells, while AZT preferentially protects activated cells against HIV infection. Considering that HIV-1 proviral DNA synthesis in resting lymphocytes is reportedly initiated at levels comparable with those of activated lymphocytes, the current data should have practical relevance in the design of anti-HIV chemotherapy, particularly combination chemotherapy.
    [Show full text]
  • Use of Pembrolizumab with Or Without Pomalidomide in HIV-Associated Non-Hodgkin's Lymphoma
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-002097 on 19 February 2021. Downloaded from Use of pembrolizumab with or without pomalidomide in HIV- associated non- Hodgkin’s lymphoma 1 1 1 1 Kathryn Lurain , Ramya Ramaswami, Ralph Mangusan, Anaida Widell, Irene Ekwede,1 Jomy George,2 Richard Ambinder,3 Martin Cheever,4 5 1 6 James L Gulley , Priscila H Goncalves, Hao- Wei Wang, 1,7 1 Thomas S Uldrick , Robert Yarchoan To cite: Lurain K, ABSTRACT INTRODUCTION Ramaswami R, Mangusan R, Background Non- Hodgkin’s lymphoma (NHL) is With current combination antiretroviral et al. Use of pembrolizumab currently the most common malignancy among people therapy (ART), the most common cancer with or without pomalidomide in living with HIV (PLWH) in the USA. NHL in PLWH is more HIV- associated among people living with HIV (PLWH) in the frequently associated with oncogenic viruses than NHL in 1 non- Hodgkin’s lymphoma. USA is non-Hodgkin's lymphoma (NHL). immunocompetent individuals and is generally associated Journal for ImmunoTherapy There is an 11- fold to 17- fold increased life- of Cancer 2021;9:e002097. with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less time risk of NHL in PLWH compared with doi:10.1136/jitc-2020-002097 + immunosuppressive than chemotherapy may decrease the general population, due in part to CD4 T cell lymphopenia but also to immune ► Additional material is infection risk, improve immune control of oncogenic published online only. To view, viruses, and ultimately allow for better lymphoma control.
    [Show full text]
  • HIV-Associated Cancers and Related Diseases
    The new england journal of medicine Review Article Dan L. Longo, M.D., Editor HIV-Associated Cancers and Related Diseases Robert Yarchoan, M.D., and Thomas S. Uldrick, M.D.​​ lusters of cases of pneumocystis pneumonia and Kaposi’s sar- From the HIV and AIDS Malignancy coma in New York and California in men who had sex with men were Branch, Center for Cancer Research, Na- tional Cancer Institute, Bethesda, MD. early harbingers of the acquired immunodeficiency syndrome (AIDS) epi- Address reprint requests to Dr. Yarchoan at C1 the National Cancer Institute, 10 Center demic. The syndrome was also soon noted to be associated with a high incidence of aggressive B-cell lymphomas. As the AIDS definition crystallized, Kaposi’s Dr., Rm. 6N106, MSC1868, Bethesda, MD 20892, or at robert . yarchoan@ nih . gov. sarcoma, aggressive B-cell lymphomas, and invasive cervical cancer were consid- ered to be AIDS-defining cancers when they developed in patients with human N Engl J Med 2018;378:1029-41. 2 DOI: 10.1056/NEJMra1615896 immunodeficiency virus (HIV) infection. Additional cancers are now known to be Copyright © 2018 Massachusetts Medical Society. associated with HIV (Table 1). The term HIV-associated cancer is used here to describe this larger group of cancers (both AIDS-defining and non–AIDS-defining cancers) that have an increased incidence among patients with HIV infection. In addition, incidental cancers also may develop in patients with HIV infection. Epidemiology and Pathogenesis of HIV-Associated Cancers Kaposi’s sarcoma and several types of aggressive B-cell lymphomas occur most often in patients with CD4+ T-cell lymphocytopenia.
    [Show full text]
  • HIV Drugs: the Silver Lining in the Dark Clouds Silpi Basak* to Release of Progeny Virus
    Open Access Austin Journal of HIV/AIDS Research Editorial HIV Drugs: The Silver Lining in the Dark Clouds Silpi Basak* to release of progeny virus. Along with short life cycle HIV mutate Department Microbiology, Jawaharlal Nehru Medical very rapidly. Because of mutation, the progeny virus may be superior College, India to parent virus in survival and the daughter virion may be resistant *Corresponding author: Silpi Basak, Department to Anti HIV drugs. Kozal M in 2009 has reported that resistance Microbiology, Jawaharlal Nehru Medical College, occurs in all antiretroviral therapy. Hence, the present trend is to Wardha, India use 3 antiretroviral drugs from at least 2 different classes. This 3 drug Received: November 01, 2015; Accepted: November combination therapy is commonly known as Triple Cocktail. The 02, 2015; Published: November 03, 2015 rationale behind this is if a mutation cause resistance to one drug, the Introduction other drugs can suppress the replication of resistant mutant progeny virus. Presently simpler formulas have been developed called fixed The reporting of Pneumocystis carinii (now known as dose combinations, where there is combination of 3 drugs into one Pneumocystis jiroveci) pneumonia in 4 otherwise healthy homosexual pill taken once daily in varied options. The combination therapy individuals by a General Practioner Dr. Merle A.Sande in 1981, also leads to adherence or consistency to the regime and thereby opened the Pandora’s box, letting the World know about Acquired development of resistance or making the process slower. The Immunodeficiency syndrome (AIDS). Luc Montagnier with his combination of drugs that can act on different viral targets is called colleagues from France discovered Lymphaenopathy Associated highly active Antiretroviral Therapy (HAART).
    [Show full text]
  • HIV/AIDS Research at the NCI:A Record of Sustained Excellence
    HIV/AIDS Research at the NCI: A Record of Sustained Excellence National Cancer Institute Institute Cancer National U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health HIV/AIDS Research at the National Cancer Institute: A Record of Sustained Excellence Letter from the Director of the CCR ............................................................................................................1 The Early NCI Retrovirus Experience ...........................................................................................................2 A New Virus Revealed ......................................................................................................................2 Risk Factors ........................................................................................................................................4 A Tale of Two Diseases ...............................................................................................................................5 Treating the Infection .........................................................................................................................5 Treating the Cancers .........................................................................................................................6 HIV and the Immune System: How They Interact........................................................................................8 Susceptibility to Infection, AIDS, and Related Diseases ..........................................................................10
    [Show full text]
  • International Conference on Malignancies in HIV/AIDS
    th International Conference on 17 Malignancies in HIV/AIDS October 21-22, 2019 NIH Campus Bethesda, Maryland O˜ce of HIV and AIDS Malignancy | National Cancer Institute National Institutes of Health | U.S. Department of Health and Human Services PROGRAM Day 1: October 21 8:00 a.m. – 8:15 a.m. Day 1 Poster Setup Highlighted Posters (1-8) will stay up for the entire meeting. 8:15 a.m. – 8:20 a.m. Welcome and Introduction Robert Yarchoan, M.D. Director Office of HIV and AIDS Malignancy National Cancer Institute, NIH 8:20 a.m. – 8:30 a.m. Opening Remarks Douglas R. Lowy, M.D. Acting Director National Cancer Institute, NIH 8:30 a.m. – 8:35 a.m. Presentation of NCI Director’s Career Achievement Award to Drs. Patrick S. Moore and Yuan Chang 8:35 a.m. – 9:00 a.m. Plenary 1: 25 Years of KSHV Research Patrick S. Moore, M.D., M.P.H. University of Pittsburgh 9:00 a.m. – 10:00 a.m. Session 1: Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) Moderators: Paul M. Lieberman, Ph.D. The Wistar Institute Thomas S. Uldrick, M.D., M.S. National Cancer Institute, NIH 9:00 a.m. – 9:15 a.m. O1. Functional Analysis of Human and Viral Circular RNAs During Kaposi’s Sarcoma Herpesvirus Infection Takanobu Tagawa, Ph.D. National Cancer Institute, NIH 9:15 a.m. – 9:30 a.m. O2. KSHV Manipulates Host Iron Metabolism and Antioxidant Pathways to Promote Tumorigenesis and Resist Ferroptotic Cell Death Ashlee V. Moses, Ph.D.
    [Show full text]
  • Implications for Patients and Health Policy Speaker Biographies
    What Evidence is Essential for New Medical Products? Implications for Patients and Health Policy June 13, 2014 AAAS Headquarters Washington, DC Speaker Biographies Jerry Avorn, M.D. Harvard Medical School Jerry Avorn is Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital. An internist and drug epidemiologist, he studies the intended and adverse effects of prescription drugs, physician prescribing practices, and medication policy. The division he founded and leads comprises physicians, epidemiologists, health policy analysts, statisticians, and computer scientists who work together to analyze patterns of utilization and outcomes of prescription drugs in numerous settings. Dr. Avorn pioneered the “academic detailing” approach to continuing medical education, in which non-commercial, evidence-based information about drugs is provided to doctors through educational outreach programs run by public-sector sponsors. Such programs are now in use in the U.S., Canada, Australia, and Europe. Dr. Avorn did his undergraduate work at Columbia University in 1969, received the M.D. from Harvard Medical School in 1974, and completed a residency in internal medicine at the Beth Israel Hospital in Boston. He has served as a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and is the author or co-author of over 400 papers in the medical literature on medication use and its outcomes, and of the book, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, now in its 11th printing. Robert Ball, M.D., M.P.H, Sc.M.
    [Show full text]